LOXO-BTK-18001

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with Chronic lymphocytic leukemia, Small Lymphocytic Lymphoma and Non-Hodgkin lymphoma who have failed or are intolerant to standard of care treatment
Menu